Hepatocellular Carcinoma Update, Issue 1, 2020 — Part 2: Our
interview with Dr Greten highlights the following topics as well as
cases from his practice:
Adjuvant treatment of HCC: Prospect for immunotherapy
(00:00)
Immune landscape of the liver and role of the microbiome
(04:18)
Ongoing trials evaluating immunotherapy in the (neo)adjuvant
setting for patients with HCC (07:04)
Role of immunotherapy and targeted therapy in the management of
cholangiocarcinoma (09:49)
Mechanism for the synergy between immune checkpoint inhibitors
and anti-angiogenic therapies (11:16)
Perspective on an antibody- versus a tyrosine kinase
inhibitor-based approach to targeting VEGF (14:00)
Development of shellfish allergy after exposure to dual immune
checkpoint blockade with durvalumab and tremelimumab (17:03)
Spectrum of immune-related adverse events associated with
checkpoint inhibitors (18:47)
Background and design of the Phase III IMbrave150 trial
(20:03)
Exclusion of patients with bleeding or high risk of bleeding
with untreated varices from the IMbrave150 trial (21:34)
IMbrave150: Activity and tolerability of
atezolizumab/bevacizumab versus sorafenib (24:32)
Historical response rates with single-agent tyrosine kinase
inhibitors or anti-PD-1/PD-L1 antibodies (27:46)
Potential clinical role of atezolizumab/bevacizumab as
first-line therapy for patients with advanced HCC (28:56)
Selection and sequencing of therapies for patients with HCC
(31:27)
Ongoing investigation of immune checkpoint inhibitor
combinations (34:05)
Activity of immune checkpoint inhibitors in patients with HCC
(35:57)
Case: A man in his mid-60s with a history of
hepatitis C receives cabozantinib for metastatic HCC after
experiencing disease progression on lenvatinib and pembrolizumab
(38:19)
Side effects associated with sorafenib and lenvatinib
(41:11)
Efficacy and tolerability of pembrolizumab for HCC (43:51)
Approach to first- and second-line treatment for HCC
(47:56)
Case: A man in his early 40s with chronic
hepatitis B and metastatic HCC has no evidence of disease after
treatment with pembrolizumab and surgical resection (50:55)
Case: A man in his mid-40s with uncontrolled
hepatitis C develops transaminitis after treatment with sorafenib
for HCC (55:14)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.